跳至主要内容
临床试验/NCT00907127
NCT00907127已完成1 期

Cardiac Autonomic Neuropathy in Patients With Metabolic Syndrome

University of Michigan2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2007年1月最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
入组人数
50
试验地点
2
主要终点
Cardiac autonomic testing (CAN)

研究概览

简要总结

The study will test whether damage of the heart nerves appears in patients before they develop diabetes.

详细描述

Patients who have mild abnormalities of blood sugar, high blood pressure, abnormal lipids and/or obesity can have a condition called metabolic syndrome. These patients are at high risk for diabetes and Cardiac Autonomic Neuropathy (CAN). Subjects with diagnosed metabolic syndrome will be expected to participate in the Metabolic Fitness Program which is a University of Michigan diet exercise program located in the Cardiology department at Domino Farms in Ann Arbor. Time required for this program and the study is 6 months. Clinic visits will involve Cardiac autonomic testing (CAN) procedures, PET scans and labs which will measure pre and post program intervention.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects must have IGT or IFG and two other criteria of metabolic syndrome as defined by ATP III (IFG=fasting glucose ≥ 100 mg/dl (5.5 mmol/l))
  • Definition of IGT/IFG: IGT/IFG will be defined based on the ADA diagnostic guidelines following an oral glucose tolerance test (OGTT) [2].
  • Other Required Criteria (2 of the following):
  • Waist circumference ≥ 102 cm (40 inches) in men and ≥ 88 cm (35 inches) in women, {for Asian-Americans: men ≥ 88 cm (35 inches), women ≥ 78 cm (31 inches)}
  • Triglycerides ≥ 150 mg/dl (1.7 mmol/l) - patients on drug treatment with fibrates or nicotinic acid will be presumed to have triglycerides ≥ 150mg/dl and low HDL
  • HDL cholesterol < 40 mg/dl (1.0 mmol/l) in men and < 50 mg/dl (1.3 mmol/l) in women,
  • Blood pressure ≥ 130/≥ 85 mmHg
  • Women of childbearing potential must be using contraception to prevent pregnancy

排除标准

  • Patients either pregnant or planning to become pregnant will be excluded
  • Women of childbearing potential will have a urine pregnancy test as part of the screening visit
  • Subjects who become pregnant during the study will undergo an exit visit and management of their IGT and Metabolic Syndrome will be returned to their primary care provider
  • Subjects with pre-existing cardiovascular disease including:
  • myocardial infarction
  • congestive heart failure
  • known arrhythmias
  • ventricular structural abnormalities and valvular disease
  • peripheral vascular disease
  • Subjects with hypoxemic lung or heart disease
  • Subjects with established diabetes
  • Laboratory evidence for a disease known to cause neuropathy within 3 months of screening will be an exclusion (those without known abnormality or those with a remote abnormality (> 3 months) will undergo the serologic screening)
  • Significant neurological disease (e.g., Parkinson's disease, epilepsy, recent stroke)
  • Subjects taking drugs which interfere with the uptake or metabolism of catecholamines
  • Subjects with known history of chronic kidney disease or who have significant hepatic disease (AST, ALT > 3 times upper limit for normal) or a history of previous kidney, pancreas or cardiac transplantation.
  • Subjects having taken systemic investigational drugs within the last 6 months
  • Inability or unwillingness of subject or legal guardian/representative to give written informed consent

结局指标

主要结局

Cardiac autonomic testing (CAN)

时间窗: 6 months

次要结局

  • PET Scan(6 month)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Rodica Pop-Busui

Associate Professor of Internal Medicine/MEND

University of Michigan

研究点 (2)

Loading locations...

相似试验